From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.21
First Reported 1983
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 8
Total Number 8
Disease Relevance 5.12
Pain Relevance 1.81

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

lipid binding (Bad) cell proliferation (Bad) cytosol (Bad)
mitochondrion (Bad) cytoplasm (Bad)
Anatomy Link Frequency
neurons 1
Bad (Rattus norvegicus)
Pain Link Frequency Relevance Heat
agonist 45 100.00 Very High Very High Very High
narcan 4 99.98 Very High Very High Very High
endometriosis 5 94.84 High High
Morphine 3 94.80 High High
opiate 3 90.00 High High
ischemia 50 88.28 High High
cytokine 1 88.16 High High
depression 3 87.28 High High
pain pelvic 1 86.44 High High
Opioid 1 85.88 High High
Disease Link Frequency Relevance Heat
Injury 19 98.36 Very High Very High Very High
Middle Cerebral Artery Infarction 15 97.34 Very High Very High Very High
Apoptosis 174 95.44 Very High Very High Very High
Endometriosis (extended) 6 94.84 High High
Chronic Lymphoid Leukemia 9 94.60 High High
Stroke 51 93.12 High High
Convulsion 1 91.44 High High
Stress 20 91.20 High High
Death 28 90.20 High High
Colon Cancer 7 89.72 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The pA2 value of naloxone interacting with the mu-agonist FK-33824 was significantly lower than those obtained against the two delta-agonists.
mu-agonist Binding (interacting) of associated with agonist and narcan
1) Confidence 0.21 Published 1983 Journal Eur. J. Pharmacol. Section Abstract Doc Link 6301857 Disease Relevance 0.34 Pain Relevance 1.15
activates Akt which phosphorylates Bad and enhances Bad binding by 14-3-3 [15, 33, 62].
Bad Binding (binding) of
2) Confidence 0.13 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.92 Pain Relevance 0.04
augments binding and sequestration of Bad, and thereby reduces interference of Bcl-2 and Bcl-xl protective actions by Bad [58–61].
Bad Binding (binding) of
3) Confidence 0.13 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.61 Pain Relevance 0
Results from immunoprecipitation experiments confirm enhanced Bad binding by 14-3-3?
Bad Binding (binding) of
4) Confidence 0.10 Published 2010 Journal PPAR Research Section Body Doc Link PMC2938460 Disease Relevance 0.48 Pain Relevance 0
The individual is then faced with the decision to either stay with the carrier and suffer bad reception, or pay an exorbitant cancellation fee.
bad Binding (reception) of
5) Confidence 0.03 Published 2010 Journal Frontiers in Neuroscience Section Body Doc Link PMC2987510 Disease Relevance 0 Pain Relevance 0
G(2)-M arrest was associated with phosphorylation of Bcl2 (but not BAD, Bax, or Bcl-XL): both of these end points were abrogated by treatment with a calcium chelator.
BAD Binding (associated) of
6) Confidence 0.02 Published 2002 Journal Cancer Res. Section Abstract Doc Link 12384529 Disease Relevance 0.80 Pain Relevance 0.12
Administering melatonin prior to MCAO or at the onset of reperfusion restores the injury-induced reduction in phosphorylated AKT (p-AKT), p-Bad and Bcl-XL levels and the binding of p-Bad and 14-3-3 as well as decreases caspase-3 activation.38,39 Treatment of melatonin also suppresses the immunoreactivity of cytosolic cytochrome c oxdiase in the ischemic cortex four and 24 hours after MCAO.40 To investigate whether melatonin directly inhibits neuronal apoptosis after hypoxia/ischemia, mouse striatal neurons are cultured and subjected to oxygen and glucose deprivation (OGD).
p-Bad Binding (binding) of in neurons associated with hypoxia, middle cerebral artery infarction, ischemia, injury and neurodegenerative disease
7) Confidence 0.01 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2695239 Disease Relevance 1.47 Pain Relevance 0.15
Group I received combination/sequential therapy with depot GnRH agonist (GnRH-a) for 3 months, followed by weekly RU 486 for 9 months.
agonist Binding (therapy) of associated with agonist
8) Confidence 0.01 Published 1996 Journal J. Clin. Endocrinol. Metab. Section Abstract Doc Link 8626860 Disease Relevance 0.51 Pain Relevance 0.34

General Comments

This test has worked.

Personal tools